Business Wire

Clear Creek Bio Advances Its Highly Potent SARS-CoV-2 PLpro Inhibitors in Discovery of an Oral Direct-Acting Antiviral to Treat COVID-19

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Clear Creek Bio, Inc. announced today that the company has signed a Cooperative Research and Development Agreement (CRADA) with the National Center for Advancing ...
Business Wire

Clear Creek Bio Doses First Patient in Phase 2 Outpatient Study of Brequinar to Treat COVID-19

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Clear Creek Bio, Inc. announced today that the company has dosed the first patient in the CRISIS2 study, a Phase 2 clinical study evaluating brequinar for the ...